SCHEMBL5861683

SCHEMBL5861683

COC(=O)c1ccccc1N(C)C1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
KAT2B Q92831 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
KDM4E B2RXH2 7/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 6/20 0.41
HSD17B10 Q99714 3/20 0.41
HPGD P15428 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CFTR P13569 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.40
ATM Q13315 1/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
OPRK1 P41145 1/20 0.38
PRKDC P78527 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28814162 0.87 KMT2A (0.54) KMT2AKDM4ESMN1; SMN2LMNATSHR
SCHEMBL5858670 0.84 ALDH1A1 (0.41) KAT2BBAZ2BKDM4ESMN1; SMN2LMNA
SCHEMBL5858650 0.79 KMT2A (0.37) KMT2AALDH1A1RAB9A
SCHEMBL15731239 0.77 EZH2 (0.44) KMT2ANPC1RAB9AOPRK1
SCHEMBL5859715 0.76 KDM4E (0.57) KMT2AKDM4EHSD17B10POLBOPRK1
SCHEMBL13280137 0.76 EZH2 (0.46)
SCHEMBL13276998 0.76 EZH2 (0.56) OPRK1
SCHEMBL17766545 0.75 ALDH1A1 (0.41) KMT2AKAT2BBAZ2BKDM4ESMN1; SMN2
SCHEMBL15710904 0.75 ALDH1A1 (0.44) KMT2AKDM4ESMN1; SMN2LMNATSHR
Dimethyl Phthalate SCHEMBL27721432 0.75 TSHR (0.59) KMT2AKDM4ESMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261343-A1 Anthranilamides and their use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-11-24 US claimed
US-20040029880-A1 Anthranyl amides and their use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-02-12 US claimed
US-7012081-B2 Anthranyl amides and their use as medicaments SCHERING AG (DE) 2006-03-14 US disclosed
US-20050261343-A1 Anthranilamides and their use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-11-24 US disclosed
US-20040029880-A1 Anthranyl amides and their use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261343-A1 Anthranilamides and their use as pharmaceutical agents AADAC, ANTXR2, VEGFA KMT2A 1670/4885KAT2B 2245/4885BAZ2B 1060/4885
US-20040029880-A1 Anthranyl amides and their use as medicaments AADAC, ANTXR2, VEGFA KMT2A 1807/4885KAT2B 2790/4885BAZ2B 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.